|
Indication |
For active
immunization against diphtheria, tetanus,
pertussis, poliomyelitis and invasive disease
due to Haemophilus influenzae type b
|
|
Proprietary Name |
Pentacel (Diphtheria
and Tetanus Toxoids and Acellular Pertussis
Adsorbed, Inactivated Poliovirus and Haemophilus
b Conjugate (Tetanus Toxoid Conjugate) Vaccine
|
|
Manufacturer |
sanofi pasteur |
|
Viability |
Inactivated |
|
Microorganism |
Corynebacterium diphtheriae, Clostridium
tetani, Bordetella pertussis, Hepatitis B
virus, Polioviruses type 1, 2, and 3,
Haemophilus influenzae
type b strain 1482 |
|
Dose
|
0.5 mL |
|
Route |
Intramuscular |
|
Dose form |
Suspension plus powder |
|
Appearance |
uniform, cloudy,
white to off-white (yellow tinge)
|
|
Concentration (per 0.5 mL) |
Diphtheria
toxoid,
15 Lf U
Tetanus
toxoid, 5 Lf U
Detoxified pertussis toxin, 20 mcg
Filamentous hemagglutinin,
20 mcg
Inactivated polioviruses [40 D-antigen units
(DU) Type 1 (Mahoney), 8 DU Type 2 (MEF-1), 32
DU Type 3 (Saukett)]
H. influenzae
type b, 10 mcg
covalently bound to tetanus toxoid, 24 mcg |
|
Preservatives |
None |
|
Adjuvant |
Aluminum phosphate,
0.33 mg |
|
Excipients |
Formaldehyde
(residual), ≤5 mcg
Glutaraldhyde (residual), <50 ng
Bovine serum albumin,
≤50 ng
2-phenoxyethanol (not as a preservative), 3.3 mg
Neomycin, <4 pg
Polysorbate 80,
10 ppm |
|
Allergens |
Polymyxin B sulfate, <4 pg |
|
Media |
|
|
Bordetella pertussis |
Stainer-Scholte modified by casamino acids and
dimethyl-beta-cyclodextrin |
|
Corynebacterium diphtheria |
Modified Mueller’s growth medium. Detoxified using formaldehyde Purified using serial ammonium sulfate
fractionation and diafiltration
|
|
Poliovirus Type 1, Type 2, Type 3 |
Each grown in separate
cultures of MRC-5 cells, a line of normal human
diploid cells
|
|
Clostridium tetani |
Modified Mueller-Miller
casamino acid medium without beef heart
infusion.
Detoxified using formaldehyde
and
purified using ammonium sulfate
fractionation and diafiltration.
|
|
Haemophilus influenzae type b strain
1482 |
Grown in a semi-synthetic
medium. The tetanus toxoid for conjugation to
PRP is prepared by ammonium sulfate
purification, and formalin inactivation of the
toxin from cultures of Clostridium tetani
(Harvard strain) grown in a modified Mueller and
Miller medium. The toxoid is filter sterilized
prior to the conjugation process.
|
|
Packaging |
Dose Package containing 5 vials of DTaP-IPV
component to be used to reconstitute five single
dose vials of lyophilized ActHIB vaccine
component |
|
Routine storage |
2 to 8°
C (36-46°
F)
Do Not Freeze |
|
updated
May 2010 |